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Abstract
Patent ductus arteriosus (PDA) is common among extremely preterm infants. In selected cases, surgical PDA ligation may be
required. The timing for PDA ligation may depend upon a variety of factors, with potential clinical implications. We aimed to
investigate the impact of different surgical PDA managements on ligation timing and neonatal outcomes. Inborn infants < 32
weeks of gestation and < 1500 g admitted at two tertiary Neonatal Intensive Care Units that underwent PDA ligation between
2007 and 2018 were enrolled in this retrospective cohort study and split into the following groups based on their surgical
management: on-site bedside PDA ligation (ONS) vs. referral to an off-site pediatric cardiac surgery (OFS). Neonatal charac-
teristics, surgical timing, and clinical outcomes of the enrolled infants were compared between the groups. Multivariate analysis
was performed to evaluate the impact of PDA ligation timing on significantly different outcomes. Seventy-eight neonates (ONS,
n = 39; OFS, n = 39) were included. Infants in the ONS group underwent PDA ligation significantly earlier than those in the OFS
group (median age 12 vs. 36 days, p < 0.001) with no increase in postoperative mortality and complications. The multivariate
analysis revealed a significant association between PDA ligation timing, late-onset sepsis prevalence (OR 1.045, 0.032), and
oxygen need at discharge (OR 1.037, p = 0.025).
Conclusions: Compared with off-site surgery, on-site bedside ligation allows an earlier surgical closure of PDA, with no
apparent increase in mortality or complications. Earlier PDA ligation may contribute to reduced rates of late-onset sepsis and
post-discharge home oxygen therapy, with possible cost-benefit implications.
Luigi Corvaglia and Yogen Singh contributed equally to this work.
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CUH Cambridge University Hospital
CVC Central venous catheter
hsPDA Hemodynamically significant patent ductus
arteriosus








PDA Patent ductus arteriosus
PPHN Persistent pulmonary hypertension of the newborn
PVL Periventricular leukomalacia
ROP Retinopathy of prematurity
SOM St. Orsola-Malpighi Hospital
Introduction
Patent ductus arteriosus (PDA) is common among preterm neo-
nates, with an estimated incidence of 60% in extremely-low-
birth-weight infants [1]. The rate of spontaneous ductal closure
is inversely related to gestational age, as the relative oxygen
hyposensitivity of immature tissues and the scarceness of ductal
medial muscles contribute to PDA maintenance [2]. The persis-
tence of a significant systemic-to-pulmonary transductal shunt
has been associated with adverse clinical outcomes, including
pulmonary hemorrhage, bronchopulmonary dysplasia (BPD), in-
traventricular hemorrhage (IVH), necrotizing enterocolitis
(NEC), and increased mortality [3–9].
If spontaneous closure is not achieved, PDA management
includes supportive therapy and targeted pharmacologic treat-
ment with cyclooxygenase inhibitors or paracetamol.
However, in case of ineffective or contraindicated
pharmacological closure of a hemodynamically significant
PDA, surgical ligation may be required [10]. PDA ligation
can be performed on-site, either at the infants’ bedside or in
the operation room, or off-site, if a local or mobile pediatric
cardiac surgery team is not available [11]. These different
approaches may influence the timing for PDA ligation.
Current literature comparing the effects of early vs. delayed
ligation on neonatal morbidities highlights contrasting results
[12–17], and the optimal surgical timing is still debated.
We aimed to assess whether different PDA ligation man-
agements (on-site bedside ligation vs. referral to an off-site
specialist pediatric cardiac surgical center) influence the
timing of intervention and clinical outcomes in very preterm
infants from two tertiary Neonatal Intensive Care Units
(NICU) with different pediatric cardiac surgery capabilities.
Materials and methods
Preterm infants < 32 weeks’ gestation born at the NICUs of
Cambridge University Hospital (CUH, Cambridge, UK) and of
St. Orsola-Malpighi Hospital (SOM, Bologna, Emilia-Romagna,
Italy) between January 1, 2007, and December 31, 2018, were
included in this retrospective study if, due to failed or contrain-
dicated pharmacological therapy, they underwent surgical clo-
sure of PDA, judged hemodynamically significant (hsPDA) ei-
ther on a clinical (hypotension, ventilator dependence, heart fail-
ure symptoms) and/or echocardiographic basis (left-atrial-to-aor-
tic-root ratio > 1.5 and/or pulsatile left-to-right shunt and/or mean
velocity in the left pulmonary artery > 0.6m/s and/or evidence of
diastolic reflow in the descending aorta, in coeliac or superior
mesentery artery or in cerebral arteries). Major congenital
malformations, including congenital heart defects (CHD), were
an exclusion criterion.
Infants admitted to SOM NICU had their PDA ligated at
bedside, with a timing of surgery dependent on the availability
of surgeons and anesthesiologists, usually within 48–72 h
from referral; however, in cases identified as urgent by the
neonatologist or the pediatric cardiologist, the intervention
What is known:
• Ineffective or contraindicated pharmacological closure of a hemodynamically significant PDA may require a surgical ligation.
• Available literature comparing the effect of early vs. late PDA ligation on the main neonatal morbidities has yield contrasting results.
What is new:
• The availability of a cardiac surgery service performing bedside PDA ligation allows an earlier intervention compared to patient referral to an off-site
center, with no difference in postoperative mortality and complications compared to off-site surgery.
• Earlier PDA ligation was associated with a lower prevalence of late-onset sepsis and of oxygen need at discharge, with possible cost-benefit
implications.
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was performed within 24 h. This team also provides bedside
PDA ligations off-site, covering the whole NICU network of
the Emilia-Romagna region, which includes other 7 tertiary
NICUs.
In-house cardiac surgery was not available for CUH in-
fants, as it ceased in December 2002 [18]; hence, they were
referred to specialist pediatric cardio-thoracic centers in
London, where PDA ligation was performed. In these cases,
the ligation timing depended on the availability of the neonatal
transfer team and of costs in the referral center.
Hence, based on their surgical PDA management, the infants
included in this study were allocated in the following groups: on-
site surgery (ONS, characterized by infants from SOM) vs. off-
site surgery (OFS, characterized by infants from CUH).
The echocardiographic reports of the infants were retro-
spectively reviewed, and the following parameters from the
latest pre-operative scan were recorded: PDA size and shunt
characteristics, left-atrial-to-aortic-root ratio, evidence of re-
versed end-diastolic flow in the descending aorta, and/or an-
terior cerebral artery (when available). Prior pharmacological
PDAmanagement, including the related contraindications and
adverse effects, was also reviewed; treatment failure was de-
fined by PDA persistency after ≥ 2 pharmacological courses.
The following data were recorded from the study popula-
tion: post-conceptional age, days of life and weight at surgical
intervention, peri- and postoperative mortality, and complica-
tions (within 1 week from ligation or ascribable to surgery).
Clinical outcomes included mortality rates, IVH (grade
1 to 4) [19], periventricular leukomalacia (PVL) [19],
NEC [19], bowel perforation [19], late-onset sepsis (de-
fined as relevant symptoms with positive blood culture
and/or C-reactive protein > 25 mg/L and > 5 days of
antibiotic treatment after the first 72 h of life) [20], reti-
nopathy of prematurity (ROP) [19], BPD (defined by the
need for supplemental oxygen and/or positive-pressure re-
spiratory support at 36 weeks’ post-conceptional age
[PCA]) [19, 21], persistent pulmonary hypertension
(PPHN, defined by the echocardiographic evidence of
right ventricular hypertrophy or dilation with any among
tricuspid regurgitation gradient > 40 mmHg or maximum
velocity of the tricuspid regurgitant flow > 3 m/s, flat
intraventricular septum or septal bowing into the left ven-
tricle, right-to-left shunt across the PFO and/or the DA in
the absence of CHD, and by the need for inhaled nitric
oxide) [22, 23], length of hospital stay, time needed to
achieve full enteral feeding (FEF), total duration of me-
chanical ventilation (MV), days off MV [24], and supple-
mental oxygen need at hospital discharge. NEC, IVH, and
sepsis rates before PDA ligation were also noted. Infants
deceased prior to 36 weeks’ PCA or before their first
ophthalmological screening, FEF achievement, and hospi-
tal discharge were excluded from the evaluation of the
related outcomes. Infants deceased prior to MV weaning
were assigned a 0 value in the computation of MV-free
days [24].
Statistical analysis
Data distribution was verified using Shapiro-Wilk test.
Continuous variables were expressed as median (interquartile
range [IQR]). Clinical characteristics and outcomeswere com-
pared between the two groups using Chi-square or Fisher’s
exact test for categorical variables and Mann-Whitney U test
for continuous variables. Multivariate logistic regression
models with backward elimination (likelihood ratio) including
statistically significant neonatal variables at the univariate lev-
el and those variables with a known pathophysiological rela-
tionship were built to identify independent associations with
the observed outcomes. Correlation matrix technique was
used to evaluate multicollinearity among the model variables;
absolute correlation coefficients > 0.5 indicated a high, not
tolerable cross-correlation. The Hosmer-Lemeshow test was
used to determine the goodness of fit of each logistic regres-
sionmodel. Statistical Package of Social Science (SPSS, IBM,
Chicago, IL) software, version 26, was used for statistical
analysis. Significance level was set at p < 0.05.
Ethics
The study protocol was approved by the Ethic Committee
“Area Vasta Emilia Centro–AVEC” (protocol no.231/2019/
Oss) and by the clinical audit department at Cambridge
University Hospitals (PRN no.800, study ID no.2000).
Results
As illustrated in Fig. 1, 671 neonates from CUH and 225 from
SOM were screened; of these, 47 were ruled out for the pres-
ence of exclusion criteria, whereas 2 CUH infants were ex-
cluded as data on their pharmacological PDA management
were not available due to their participation to the Baby-
OSCAR trial [25]. Seventy-eight neonates underwent PDA
ligation and were included in the study: 39 in the ONS group
and 39 in the OFS group. The yearly distribution of the study
infants over the 12-year study period, illustrated in Fig. 2, did
not differ significantly between the two centers.
Neonatal and PDA characteristics of the study groups are
shown in Table 1. Infants in the ONS group showed slightly
but significantly higher CRIB II scores and higher rates of C-
section compared to those in the OFS group. No significant
between-group differences were observed in the other neona-
tal variables that were evaluated. The first echocardiographic
scan was performed at an earlier age in the ONS group com-
pared to the OFS one. Nevertheless, pre-ligation echocardio-
graphic features and pharmacological PDA management did
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not differ between the groups. In both centers, pharmacolog-
ical closure was undertaken if the echocardiographic and clin-
ical criteria for hsPDA described in the methods section
persisted for > 48 h. Similar pharmacological dosages were
used in the two groups (indomethacin, 0.2 mg/kg/day for up to
3 days; ibuprofen, 10 mg/kg on day 1, followed by 2 to 3 daily
doses of 5 mg/kg; paracetamol, 15 mg/kg 6 h for 3 days).
Since 2010, ibuprofen replaced indomethacin as first-line
treatment. Paracetamol was introduced from 2016 and was
mainly used in case of failure or contraindication of ibuprofen
treatment. The number of pharmacological courses attempted
before PDA ligation in each center and the medication used
for each course are shown in Table 1; no significant differ-
ences were observed between the two cohorts. However, phar-
macological PDA closure was attempted sooner in the ONS
group compared to the OFS one (median age at first course: 3
[IQR 2–4] vs. 7 [IQR 4–10] days, p < 0.001).
ONS infants underwent PDA ligation significantly earlier
(median age 12 [IQR 7–21] vs. 36 [IQR 28–52] days, p <
0.001) compared to those that were transferred to a referral
cardio-thoracic center. As expected, the weight at surgical inter-
vention in the ONS group was significantly lower. Moreover, a
significantly higher percentage of infants in the latter group re-
quired ventilation at the time of PDA ligation. Vital parameters at
the end of surgery were available for the ONS group and have
been provided as Supplementary Information. There was no dif-
ference in perioperative or postoperative mortality between the
two groups. Post-surgical complications included pleural effu-
sion (ONS, n = 1), vocal cord palsy (ONS, n = 1; OFS, n = 2),
pneumothorax (OFS, n = 1), and transient left pulmonary artery
narrowing (OFS, n = 1). As reported in Table 2, the rates of post-
surgical complications and of sepsis onset within 1 week after
surgery did not differ between the groups.
The main study outcomes are detailed in Table 2. No
between-group difference in the overall rates of mortality,
PVL, NEC, time to FEF, and length of hospitalization was
observed. The prevalence of IVH and sepsis during hospital
stay was significantly higher in the OFS group compared to
the ONS group (p = 0.007 and p = 0.042, respectively). When
the pre-ligation period was analyzed separately, increased
rates of sepsis (p = 0.007) and NEC (p = 0.003) were con-
firmed in the OFS group.
With regard to respiratory outcomes, MV duration and
PPHN rates did not differ significantly between the
groups; however, the prevalence of BPD at 36 weeks’
PCA and of oxygen need at discharge were significantly
higher in the OFS group compared to ONS (p = 0.008 and
p = 0.013, respectively).
Multiple logistic regression models were built to adjust the
observed results for relevant clinical variables. Due to the
evidence of a significant cross-correlation between the centers
and PDA ligation timing (correlation coefficient = 0.725, p <
0.001), only the latter was included in the models. Each mul-
tivariate regression model also included CRIB II scores and
the mode of delivery, which differed significantly between the
study groups at the univariate analysis, and the year of birth, in
order to address potential time effects due to the advances in
neonatal care, occurred during the 12-year study period. Time
to FEF was specifically added to the late-onset sepsis model,
whereas MV duration and PPHN development were included
in the models for BPD and oxygen need at discharge. No
collinearity issues were observed. The Hosmer-Lemeshow
test revealed an adequate fit for all the models (p > 0.05).
Results of the final regression models ensuing from back-
ward selection are summarized in Table 3. Logistic regression
confirmed a significant and independent correlation between
Fig. 1 Flow chart of the study
inclusion. CHD, congenital heart
defect; DOB, date of birth;
ECHO, echocardiography; ONS,
on-site surgery; OFS, off-site
surgery; PDA, patent ductus
arteriosus
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PDA ligation timing, late-onset sepsis (p = 0.032, OR 1.045
[1.004–1.088]), and oxygen need at discharge (p = 0.025, OR
1.037 [1.004–1.170]). MV duration was significantly associ-
ated with both BPD (p = 0.016, OR 1.088 [1.016–1.165]) and
oxygen need at discharge (p = 0.030, OR 1.041 [1.004–
1.180]). A significant association between IVH development
and CRIB II score (p = 0.015, OR 1.245 [1.043–1.486]), but
not PDA ligation timing, was also observed.
Fig. 2 Yearly distribution of
PDA ligation cases in the two
study groups (on-site [ONS] vs.
off-site surgery [OFS])
Table 1 Clinical characteristics,
echocardiographic features, and
management of patent ductus
arteriosus (PDA) in the on-site
surgery (ONS) and off-site
surgery (OFS) groups. Results of
between-group comparisons are
also reported; significant p-values
are highlighted in italic
Neonatal characteristics ONS (n = 39) OFS (n = 39) p Value
Gestational age (weeks), median (interquartile range [IQR]) 25 (23.3–26.7) 25.1 (24.3–26.4) 0.350
Birth weight (g), median (IQR) 670 (560–820) 700 (600–797) 0.569
Apgar score at 5 min, median (IQR) 8 (5–8) 7 (6–8) 0.915
CRIB II score, median (IQR) 15 (12–16) 13 (11–14) 0.016
Sex (males), n (%) 24 (61.5) 24 (61.5) 1.000
Intrauterine growth restriction, n (%) 6 (15.4) 9 (23.1) 0.389
Delivery mode (C-section), n (%) 25 (64.1) 14 (35.9) 0.013
Antenatal steroids (complete course), n (%) 18 (46.2) 25 (64.1) 0.111
Age at first echocardiography (days), median (IQR) 2 (2–3) 4 (2–8) < 0.001
Pre-ligation PDA characteristics
Size (mm/kg), median (IQR) 4.1 (3–4.8) 4.2 (3.7–4.7) 0.245
LA:Ao ratio, median (IQR) 1.9 (1.7–2.1) 1.9 (1.8–2) 0.655
Pharmacological PDA closure attempted, n (%) 31 (79.5) 32 (82.1) 0.774
Number of pharmacological courses
1, n (%) 14 (45.2) 14 (43.8) 0.611
2, n (%) 17 (54.8) 17 (53.1)
3, n (%) 0 (0) 1 (3.1)
Medication used for pharmacological PDA closure
Ibuprofen, n (%) 33 (68.7) 29 (56.9) 0.154
Indomethacin, n (%) 8 (16.7) 17 (33.3)
Paracetamol, n (%) 7 (14.6) 5 (9.8)
PDA recurrence after pharmacological closure, n (%) 12 (30.8) 7 (17.9) 0.146
Age at PDA ligation (days), median (IQR) 12 (7–21) 36 (28–52) < 0.001
Weight at PDA ligation (g), median (IQR) 630 (543–824) 1080 (868–1300) < 0.001
Ongoing mechanical ventilation at PDA ligation, n (%) 34 (87.2) 23 (59) 0.010
IQR interquartile range, LA:Ao ratio left-atrium-to-aortic-root ratio, PDA patent ductus arteriosus
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Discussion
The present results show that the availability of a local cardiac
surgery service performing bedside ligation allows an earlier
surgical closure of PDA compared to patient referral to an off-
site tertiary cardio-thoracic center, with no difference in post-
operative mortality and complication rates. We also identified
a significant association between a later off-site PDA ligation,
an increased prevalence of late-onset sepsis, and increased
oxygen requirements at discharge.
Surgical ligation is considered when pharmacological PDA
closure is either contraindicated or has failed to elicit clinical
and echocardiographic improvement, with persistent mechan-
ical ventilation dependence [10]. Based on the local availabil-
ity of pediatric cardio-thoracic surgical services, operative
practices are prone to certain inter-institutional variability.
When these services are not available, either locally or as a
mobile team provided from a referral center, the infants’ trans-
fer to a referral center for PDA ligation is common practice;
however, off-site transportation often requires reasonably sta-
ble clinical condition and may be associated with adverse
events including hypothermia, line dislodgement, and un-
planned extubation [10].
In the present study, bedside PDA ligation more than
halved the surgical timing compared to off-site interven-
tions, with similar rates of postoperative complications,
confirming the safety of this procedure, when performed
by an experienced team.
The timing of PDA ligation in the referral center also
depends on cost availability, which may contribute to
some delay in surgical intervention, prolonging the per-
sistence of an hsPDA. On the other hand, bedside PDA
ligation has proved to be a safe and effective technique,
with surgical outcomes comparable to operating room clo-
sure, low rates of postoperative infection, and reduced
resource utilization [26, 27].
Nevertheless, additional factors, such as the earlier age
of the ONS cohort at the first echocardiographic evalua-
tion and at the first pharmacological attempt of PDA clo-
sure, may have partially contributed to the significant dif-
ferences in PDA ligation timing observed between the two
study groups.
Table 2 Clinical outcomes in the on-site surgery (ONS) and off-site surgery (OFS) groups and results of between-group comparison. Significant p-values
of between-group comparisons are highlighted in italic
Clinical outcomes ONS (n = 39) OFS (n = 39) p Value
Surgical complications, n (%) 2 (5.1) 5 (12.8) 0.235
Post-ligation pulmonary hypertension, n (%) 3 (7.7) 1 (2.6) 0.615
Post-surgical sepsis (< 7 days after ligation), n (%) 2 (5.1) 4 (10.2) 0.675
Mortality, n (%) 8 (20.5) 3 (7.7) 0.192
Sepsis, n (%) 24 (61.5) 32 (82.1) 0.044
Sepsis, before PDA ligation, n (%) 8 (20.5) 26 (66.7) < 0.001
Intraventricular hemorrhage No IVH, n (%)
Grade I–II, n (%)








IVH, before PDA ligation, n (%) No IVH, n (%)
Grade I–II, n (%)








Periventricular leukomalacia, n (%) 5 (12.8) 2 (5.1) 0.235
Necrotizing enterocolitis (Bell’s stage ≥ 2), n (%) 10 (25.6) 17 (43.6) 0.096
Necrotizing enterocolitis (Bell’s stage ≥ 2),
before PDA ligation, n (%)
1 (2.6) 11 (28.2) 0.003
Time to full feeding (days), median (IQR)° 49 (33–61) 38 (24–51) 0.070
Mechanical ventilation (days), median (IQR) 29 (20–41) 33 (25–47) 0.185
Time off mechanical ventilation (days), median (IQR) 88 (44–98) 94 (74–110) 0.112
Bronchopulmonary dysplasia at 36 weeks, n (%)° 21 (70) 36 (94.4) 0.004
Retinopathy of prematurity° No ROP
Stage I, n (%)
Stage II, n (%)










Length of hospital stay (days), median (IQR)° 120 (90–138) 124 (119–143) 0.208
Oxygen need at discharge, n (%)° 6 (15.4) 19 (48.7) 0.004
°Infants deceased prior to outcome evaluation excluded from the analysis
IQR interquartile range, IVH intraventricular hemorrhage, ROP retinopathy of prematurity, PDA patent ductus arteriosus
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Current literature comparing neonatal outcomes in re-
lation to the surgical timing of PDA ligation is limited.
In 2015, Ibrahim et al. [16] reported a shorter MV dura-
tion and a lower fraction of inspired oxygen at 24 h
postoperatively in preterm infants who underwent PDA
ligation within the first 3 weeks, compared to a later
intervention; however, they found no between-group dif-
ference in BPD development. Two years later, Youn
et al. [17] retrospectively investigated neonatal outcomes
after early (< 2 weeks) and late (≥ 2 weeks) PDA liga-
tion: No difference in the main morbidities and mortality
occurred, but a significant association between PPHN
development during the first week of life and late liga-
tion was observed.
In the present study, the prevalence of BPD was higher
in both groups compared to that reported in extremely
preterm infants by other cross-continent neonatal network
studies [28–30]. While the correlation with BPD did not
reach statistical significance in the multivariate model, we
found a significant independent association between PDA
ligation timing and oxygen need at discharge. Since no
difference in the length of NICU stay was observed, it is
likely that infants requiring post-discharge oxygen supple-
mentation represented the subgroup with most severe
BPD.
The association between BPD development and PDA
treatment is an active matter of debate: Current evidence
has not clarified whether this morbidity may be related to
the negative effects of the ductal shunt itself, or indirectly
to its treatment modality. Increased BPD rates in preterm
infants undergoing PDA ligation compared to pharmaco-
logical treatment have been reported [31–33] and con-
firmed by a meta-analysis [34]; however, data from a
large American network showed that reduced ligation
rates were not accompanied by a consistent BPD decrease
[35]. Schena et al. [36] observed that surgically treated
neonates who developed BPD underwent PDA ligation
significantly later compared to those without BPD. The
prolonged exposure of the developing lung to pulmonary
overflow has been proposed as a likely underlying mech-
anism, although other variables could have contributed to
this finding. The presence of methodological biases, such
as the lack of standardized definitions for both BPD and
hsPDA [37] and the adoption of different approaches for
PDA closure, may have also contributed to these contro-
versial results [10].
The cerebral hemodynamic disturbances caused by an
hsPDA may be involved in the development of IVH, es-
pecially during postnatal transition. We observed a higher
IVH prevalence in OFS infants, who underwent PDA li-
gation significantly later, but logistic regression showed
no association between the ligation timing and IVH de-
velopment. Moreover, all the cases in the ONS group
occurred before surgical ligation, consistent with the typ-
ical early timing of IVH onset [5, 38]. On the other hand,
independent association between IVH occurrence and in-
creasing CRIB II scores was observed, consistently with
available literature [39].
As for gastrointestinal complications, multiple NEC
cases occurred during the pre-ligation period in infants
undergoing a later PDA surgery, whereas only one infant
in the ONS group developed NEC before ligation. The
detrimental effects of a persistent hsPDA on splanchnic
circulation, which may increase the risk for ischemic-
related gut complications, support this observation [40,
41]. However, other variables, such as different feeding
Table 3 Results of the final logistic regression models (backward selection); significant p-values are highlighted in italic
Model R2 Variables B SE OR (95% CI) p Value
Late-onset sepsis 0.268 CRIB II score 0.183 0.110 1.201 (0.968–1.491) 0.096
Time to FEF 0.028 0.015 1.028 (0.999–1.959) 0.061
Ligation timing 0.044 0.020 1.045 (1.004–1.088) 0.032
Constant -3.758 1.712 0.023 0.027
Bronchopulmonary dysplasia 0.437 CRIB II score 0.239 0.160 1.269 (0.927-1.738) 0.137
MV duration 0.084 0.035 1.088 (1.016–1.165) 0.016
Ligation timing 0.040 0.025 1.041 (0.992–1.092) 0.106
Constant -4.698 2.365 0.009 0.047
O2 need at discharge 0.328 MV duration 0.040 0.019 1.041 (1.004–1.180) 0.030
Ligation timing 0.036 0.016 1.037 (1.004–1.170) 0.025
Constant -3.119 0.853 0.044 < 0.001
Intraventricular hemorrhage 0.145 CRIB II score 0.219 0.090 1.245 (1.043–1.486) 0.015
Ligation timing 0.025 0.015 1.026 (0.996–1.056) 0.094
Constant -3.088 1.397 0.046 0.027
FEF full enteral feeding, MV mechanical ventilation, OR odds ratio, SE, standard error
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managements adopted by the two centers in the presence
of an hsPDA, may have contributed to this finding. Of
note, most NEC cases in the OFS group occurred after
FEF achievement.
We observed a significant correlation between the
prevalence of sepsis and PDA ligation timing, indepen-
dent of other covariates. A major risk factor for late-
onset sepsis in NICU settings is the presence of central
venous catheters (CVC) [42]. The higher pre-ligation
NEC prevalence observed in the OFS group may have
protracted the permanence of CVC for therapeutic and
nutritional reasons. Moreover, PDA ligation itself requires
a perioperative withholding of enteral feeds, further
prolonging the need for long lines while building up en-
teral nutrition in the post-surgical phase, thus further in-
creasing the risk of sepsis. However, since data on CVC
permanence were not available for part of the study co-
hort, this hypothesis cannot be confirmed by the present
data.
The following study limitations need to be acknowl-
edged. The relatively small size of the study sample
prevented the use of more refined and accurate statistical
strategies (e.g., the use of a propensity score), whereas the
retrospective patient inclusion could not exclude a possi-
ble selection bias. Moreover, the bicentric nature of the
study and its 12-year period might have contributed to the
heterogeneity of the study sample. To address this issue,
the observed results were adjusted also for the year of
birth. However, given the small percentage of neonates
requiring PDA ligation, which is estimated around 6%
of infants with hsPDA [1], multicenter studies will be
necessary to achieve powered comparisons of different
surgical approaches. Eventually, data on ventilation mo-
dalities were not fully available for the whole cohort and
therefore were not included in the study outcomes.
Although our results need to be further validated, there
appear to be cost-benefit implications. The clinical com-
plications that were found to be associated with later PDA
ligation have a major impact on health care services.
These costs may not offset the financial resources re-
quired to set up a local service of pediatric cardiac sur-
gery, with a mobile operative team providing bedside li-
gation, which is currently unavailable in the UK.
Conclusion
The availability of a local cardiac surgery service performing
bedside PDA ligation allows an earlier surgical timing compared
to patient referral to an off-site tertiary cardiac surgery center,
with no increase in postoperative mortality and complications.
Although larger studies are needed to confirm this finding on a
global scale, decreasing the timing for PDA ligationmay also aid
to reduce the occurrence of specific clinical associations (such as
decreased need of home oxygen therapy on discharge and
reduced rate of late-onset sepsis), with potential implications on
health care resources.
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